Antibodies against animal growth hormones appearing in patients treated with human growth hormone: their specificities and influence on growth velocity

Abstract. The appearance of anti-human growth hormone (hGH) and anti-non-hGHs antibodies in 27 patients with idiopathic hypopituitarism, treated for periods of 6—18 months with three different preparations of hGH, was investigated. The preparations induced antibodies to GH in 21 out of the 27 patients: 10 patients produced exclusively an anti-non-hGH response, whereas 11 generated both anti-non-hGH and anti-hGH antibodies. The levels of antibodies against hGH had low correlation with decreased growth velocity, whereas those for the antibodies against non-hGHs did not correlate with decreased growth velocity.

Download Full-text

Comparison of the pharmacological properties of pituitary and biosynthetic human growth hormone

Acta Endocrinologica ◽

10.1530/acta.0.1140124 ◽

1987 ◽

Vol 114 (1) ◽

pp. 124-131 ◽

Cited By ~ 21

Author(s):

Karin Damm Jørgensen

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Human Growth ◽

Growth Hormones ◽

Pharmacological Properties ◽

Obese Mice ◽

Sleeping Time ◽

Test Systems ◽

Pharmacological Test ◽

Hexobarbital Sleeping Time

Abstract. Biosynthetic human growth hormone was compared with pituitary human growth hormone and pituitary 22 K in the weight gain and the tibia test. The three preparations were found to be equipotent. Furthermore, the growth hormones were compared in various pharmacological test systems. All three preparations were found to have a marked antidiuretic and antinatriuretic effect in the rat and to cause a significant shortening of the hexobarbital sleeping time in mice. Biosynthetic and pituitary preparations had the same diabetogenic activity in obese mice, and the growth hormones did not differ with respect to pharmacological profiles in the test systems applied.

Download Full-text

Human growth hormone but not ovine or bovine growth hormones exhibits galactopoietic prolactin-like activity in organ culture from bovine lactating mammary gland

Molecular and Cellular Endocrinology ◽

10.1016/0303-7207(83)90165-x ◽

1983 ◽

Vol 33 (2-3) ◽

pp. 169-182 ◽

Cited By ~ 48

Author(s):

A. Gertler ◽

N. Cohen ◽

A. Maoz

Keyword(s):

Growth Hormone ◽

Mammary Gland ◽

Organ Culture ◽

Human Growth Hormone ◽

Human Growth ◽

Growth Hormones ◽

Lactating Mammary Gland

Download Full-text

Reactivity of Non-Primate Growth Hormones and Prolactins with Human Growth Hormone Receptors on Cultured Human Lymphocytes

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jcem-44-5-838 ◽

1977 ◽

Vol 44 (5) ◽

pp. 838-849 ◽

Cited By ~ 42

Author(s):

MAXINE A. LESNIAK ◽

PHILLIP GORDEN ◽

JESSE ROTH

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Hormone Receptors ◽

Human Lymphocytes ◽

Human Growth ◽

Growth Hormones ◽

Growth Hormone Receptors

Download Full-text

Results of Four Years of Intermittent Human Growth Hormone (hGH) and Fluoxymesterone Therapy in Hypopituitary Dwarfism

PEDIATRICS ◽

10.1542/peds.65.3.562 ◽

1980 ◽

Vol 65 (3) ◽

pp. 562-566

Author(s):

Rebecca T. Kirkland ◽

R. B. Harrist ◽

George W. Clayton

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Growth Velocity ◽

Combined Therapy ◽

Combined Treatment ◽

Human Growth ◽

First Year ◽

Average Growth ◽

Group A ◽

Second Year

In order to investigate the synergistic effect on growth of human growth hormone (hGH) and an anabolic agent, fluoxymesterone, 28 children with hypopituitarism received the combined therapy in an intermittent regimen for one to four years. Fourteen of the children had received prior therapy with growth hormone alone. All of the children were prepubertal. They had a mean chronologic age (CA) of 9.53 years ± 2.33 SD and mean bone age (BA) of 6.05 years ± 2.07 SD. The change in BA/change in height age (HA) ≤1 in 15 of the 28 children (53.6%). The change in HA/change in CA was ≥1 in 17 of 28 (60.7%). The 14 children who had received hGH therapy alone, group A, had a growth velocity of 4.72 cm/yr ± 1.24 SD in the year prior to the combined treatment. This did not differ significantly from the average growth velocity of 5.58 cm ± 1.47 SD during the first year of combined therapy. The average growth velocity of the remaining 14 children, group B, during the first year of combined therapy was 6.72 cm/yr ± 1.01 SD. This differed significantly from the growth velocity of group A before combined therapy (P < .001) and also during the first year of combined therapy (P < .025). The overall mean growth rate in the second year, 5.33 cm, was less than that of the first year, P < .025, and was not different from that achieved with hGH alone. Furthermore, the velocity in each of the following years was similar to that of the second year. The use of intermittent combined therapy in the doses employed in this study does not appear to be of benefit in prolonging catch-up growth in hypopituitary patients. This regimen provides acceleration of growth in the initial year of therapy for those children who have not received prior hGH therapy.

Download Full-text

Extended recombinant human growth hormone treatment after renal transplantation in children.

Journal of the American Society of Nephrology ◽

10.1681/asn.v212s274 ◽

1992 ◽

Vol 2 (12) ◽

pp. S274

Author(s):

R N Fine ◽

O Yadin ◽

L Moulten ◽

P A Nelson ◽

M I Boechat ◽

...

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Growth Velocity ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Bone Age ◽

Hormone Treatment ◽

Height Velocity ◽

Time Interval ◽

Mean Values

Recombinant human growth hormone (rhGH) was administered to 13 pediatric renal allograft recipients, ages 7.6 to 17.7 yr, who were 14 to 92 months posttransplant and growth retarded as manifested by either a standard deviation (SD) more negative than -2.00 or a height velocity index of less than 25%. The rhGH was given either daily or thrice weekly (0.375 mg/kg/wk) for a period of 12 to 36 months. Growth velocity increased from 2.7 +/- 2.1 SD for the 12-month period before the initiation of treatment of 6.3 +/- 2.9 SD (P less than 0.00005) and 5.2 +/- 2.9 SD (P less than 0.02) after 12 and 24 months of treatment, respectively. Although individual recipients had improvement in their SD scores, the mean values did not increase despite the increased growth velocity. Except for a 0.5-yr increase over 24 months in two recipients, the bone age did not increase at a rate greater than the increase in chronologic age. Four rejection episodes occurred in two recipients during rhGH treatment--an incidence not greater than that which occurred during a comparable time interval before the initiation of treatment. The calculated creatinine clearance declined from 66 +/- 26 SD mL/min/1.73 m2 at the initiation of treatment to 55 +/- 30 SD mL/min/1.73 m2 at 24 months and 52 +/- 28 SD mL/min/1.73 m2 (P = not significant).(ABSTRACT TRUNCATED AT 250 WORDS)

Download Full-text